FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
RegulatoryapprovedLisrayaPositive
AI Analysis
Summary
The FDA approved Lisraya (brepocitinib) tablets for treating dermatomyositis in adults, marking the first oral drug approved for this indication.
Outcome Details
FDA approval for Lisraya (brepocitinib) tablets for treatment of dermatomyositis in adults. First oral drug indicated for this condition.
Importance:9/10
Sentiment:
0.95
FDA approvalfirst-in-classdermatomyositisoral medicationregulatory
Related Companies
Read the original article
Published by FDA Press Releases on August 27, 2026 7:11 PM